Jupiter Neurosciences, Inc. Common Stock
$2.86
Market Cap
$3.97M
Shares Outstanding
1.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 3, 2024
Round Lot
100
Locale
US
Day Open
$3.05
Day High
$3.14
Day Low
$2.86
Volume
17.7K
VWAP
$2.96
Prev Close
$3.01
Transactions
--
Acc. Volume
--
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
Jupiter Neurosciences, Inc. Common Stock (JUNS) closed the 2026-09-18 session at $2.86, down 4.98% versus the previous close (-0.15). The stock opened at $3.05 and traded between $2.86 and $3.14 during that session. Session trading volume was 18K shares. The volume-weighted average price (VWAP) is $2.96.
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
Jupiter Neurosciences, Inc. Common Stock has a market capitalization of $4.0 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. JUNS is listed on the XNAS exchange. The company employs approximately 5 people. Jupiter Neurosciences, Inc. Common Stock is headquartered in JUPITER, FL. The recorded listing date is 2024-12-03.
On this page you can find market JUNS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.